Omega-3 fatty acid formulation does not reduce major adverse cardiovascular events in patients with high cardiovascular risk, reports a new study.

‘Omega-3 fatty acid formulation does not reduce major adverse cardiovascular events in patients with high cardiovascular risk.
’

A new randomized trial studies the effects on heart outcomes of a carboxylic acid formulation of DHA and EPA (omega-3 CA) with documented favorable impacts on lipid and inflammatory markers in patients with atherogenic dyslipidemia and high cardiovascular risk.




In this clinical trial of 13 078 patients that was stopped early, daily supplementation with omega-3 fatty acids, than corn oil, resulted in no significant difference in a composite outcome of major adverse heart disease events.
These findings do not support using this omega-3 fatty acid formulation to decrease major adverse cardiovascular events in high cardiovascular risk patients.
Source-Medindia